{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:23:10Z","timestamp":1790392990625,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005905","name":"French Medicines Agency","doi-asserted-by":"publisher","award":["2013-S081"],"award-info":[{"award-number":["2013-S081"]}],"id":[{"id":"10.13039\/501100005905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.therap.2018.12.007","type":"journal-article","created":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T20:33:36Z","timestamp":1546115616000},"page":"469-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in France"],"prefix":"10.1016","volume":"74","author":[{"given":"Anne","family":"B\u00e9nard-Laribi\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Noize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Oliver","family":"Girodet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Lassalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dureau-Pournin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Droz-Perroteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Fourrier-R\u00e9glat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2018.12.007_bib0195","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2515\/therapie\/2013039","article-title":"Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice?","volume":"68","author":"Le Jeunne","year":"2013","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.12.007_bib0200","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.281.18.1728","article-title":"The safety of newly approved medicines: do recent market removals mean there is a problem?","volume":"281","author":"Friedman","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2018.12.007_bib0205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2018.12.007_bib0210","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.2017.14567","article-title":"Ten steps the Federal Government should take now to reverse the opioid addiction epidemic","volume":"318","author":"Kolodny","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2018.12.007_bib0215","doi-asserted-by":"crossref","first-page":"e0183354","DOI":"10.1371\/journal.pone.0183354","article-title":"Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: A pilot randomized controlled trial","volume":"12","author":"Coffin","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2018.12.007_bib0220","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/clpt.2012.30","article-title":"The use of observational health-care data to identify and report on off-label use of biopharmaceutical products","volume":"91","author":"Morris","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2018.12.007_bib0225","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2515\/therapie\/2015009","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.12.007_bib0230","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1177\/0333102415570497","article-title":"Triptans use and overuse: a pharmacoepidemiology study from the French health insurance system database covering 4.1 million people","volume":"35","author":"Braunstein","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/j.therap.2018.12.007_bib0235","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2018.12.007_bib0145","series-title":"Guideline on good pharmacovigilance practices (GVP). Annex I \u2013 Definitions (Rev 4)","author":"European Medicines Agency","year":"2017"},{"key":"10.1016\/j.therap.2018.12.007_bib0240","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ki.2015.101","article-title":"Combined use of nonsteroidal anti-inflammatory drugs with diuretics and\/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury","volume":"88","author":"Dreischulte","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2018.12.007_bib0245","doi-asserted-by":"crossref","first-page":"e8525","DOI":"10.1136\/bmj.e8525","article-title":"Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study","volume":"346","author":"Lapi","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2018.12.007_bib0250","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1574886311308010009","article-title":"Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?","volume":"8","author":"Lertxundi","year":"2013","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.therap.2018.12.007_bib0165","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"American Geriatrics Society 2015\u00a0updated Beers Criteria for potentially inappropriate medication use in older adults","volume":"63","author":"By the American Geriatrics Society 2015\u00a0Beers Criteria Update Expert Panel","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.therap.2018.12.007_bib0255","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00787-014-0668-y","article-title":"Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013","volume":"24","author":"Verdoux","year":"2015","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.therap.2018.12.007_bib0260","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","article-title":"Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis","volume":"73","author":"Galling","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.therap.2018.12.007_bib0265","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00787-013-0399-5","article-title":"Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review","volume":"22","author":"Martinez-Ortega","year":"2013","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.therap.2018.12.007_bib0270","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pds.2307","article-title":"Association of French PharmacoVigilance Centres. A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006","volume":"21","author":"Sommet","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2018.12.007_bib0190","series-title":"Bon usage des m\u00e9dicaments en cas de vague de chaleur\u00a0\u2013\u00a0mise au point","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9","year":"2017"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718302646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718302646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:14Z","timestamp":1758567194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595718302646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0040595718302646"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.12.007","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in France","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2018.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}